Notably, cMET skip14 mutation was missed by solid NGS in a recent Canadian study (VALUE), which examined clinical outcomes and utility of liquid biopsy in naïve stage IV lung adenocarcinoma patients. The gene discussed is MET; the disease is lung adenocarcinoma.